Altered cell adhesion is causally involved in tumor progression, and the identification of novel adhesion molecules altered in tumors is crucial for our understanding of tumor biology and for the development of new prognostic and therapeutic strategies. Here, we provide evidence for the epigenetic downregulation in breast tumors of the A Desintegrin And Metalloprotease domain 23 gene (ADAM 23), a member of a new family of surface molecules with roles in cell-cell adhesion and/or cellmatrix interactions. We examined the mRNA expression and methylation status of the 5 0 upstream region of the ADAM23 gene in different breast tumor cell lines as well as in primary breast tumors. We found ADAM23 5 0 hypermethylation in eight out of 12 (66.7%) tumor cell lines and in nine out of 13 (69.2%) primary tumors. Promoter hypermethylation was strongly associated with reductions in both mRNA and protein expression, with a threshold of 40-60% of modified CpG dinucleotides being required for the complete silencing of ADAM23 mRNA expression. Treatment of MCF-7 and SKBR-3 cell lines with 5 0 -Aza-2 0 -deoxycytidine led to a reactivation of ADAM23 mRNA expression and a marked decrease in the methylation level. It is worth noting that primary breast tumors with a more advanced grade showed a higher degree of methylation, suggesting that the adhesion molecule ADAM23 may be downregulated during the progression of breast cancer.
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Introduction
Breast cancer accounts approximately for one-fifth of all deaths in women aged 40-50 years (Radice and Redaelli, 2003) . When breast carcinomas remain confined to breast tissue, cure rates exceed 90%; however, if metastases have developed, prognosis is poor, with 5-year survival rates usually being less than 20% (Jemal et al., 2003) . Breast cancer progression and metastases formation are a multistep process resulting from a series of genetic changes (Welch et al., 2000) .
An increasing body of evidence indicates that altered cell adhesion is causally involved in tumor progression and metastases formation rather than merely being a consequence of it (Cavallaro and Christofori, 2001; Okegawa et al., 2002) . Genetic alterations in two main groups of adhesion molecules, cadherins and cell adhesion molecules (CAMs), have been implicated in tumor malignancy and the identification of novel classes of adhesion molecules altered in human cancers is crucial for extending our understanding of tumor biology and for the development of new prognostic and therapeutic strategies (Cavallaro and Christofori, 2001; Okegawa et al., 2002) .
The ADAMs (A Desintegrin And Metalloprotease domains) comprise a family of membrane-anchored cell surface proteins with a common structural organization, including metalloprotease, disintegrin, cystein-rich, epidermal growth factor-like, transmembrane and cytoplasmatic domains. The ADAMs are unique among cell surface proteins in possessing both a potential adhesion domain and a potential protease domain (Wolfsberg et al., 1995a, b; Black and White, 1998; Primakoff and Myles, 2000) . In addition, the cytoplasmatic tails of many ADAMs contain sequence homology 3 binding sites, suggesting that they may interact with intracellular signaling and cytoskeletal systems (Weskamp et al., 1996; Howard et al., 1999; Cousin et al., 2000; Suzuki et al. 2000) .
Cell-cell and cell-matrix interactions are known to determine cell-adhesion, cell migration and proliferation processes that are directly involved in tumor development and progression. Owing to the ability to perform both functions, some members of the ADAM family have been suggested to play an important role in human cancers. ADAM11 was originally identified as a candidate tumor suppressor gene involved in human breast cancer (Emi et al., 1993) , whereas several ADAM members (ADAM 9, 10, 11 and 15) have been proposed to be responsible for pathological features of hematological malignancies (Wu et al., 1997) . ADAM2 has recently been identified as a putative cancer/testis antigen expressed in renal cancer (Scanlan et al., 2002) . In addition, ADAM10 is overexpressed in pheochromocytomas and neuroblastomas, while the expression of ADAMs 9, 10 and 17 is differentially regulated by androgen in the androgen-responsive LNCaP prostate cancer cell line (McCulloch et al., 2000) . The overexpression of ADAM15 in NIH3T3 cells appears to enhance cell-cell interactions, as suggested by decreased cell migration, altered cell morphology and increased cell adhesion (Herren et al., 2001) . Finally, other family members such as ADAM17 (TACE -TNF-a converting enzyme) have been proposed to play an important role in tumor progression through their participation in the proteolytic activation of growth factor precursors of relevance to cancer, such as tumor necrosis factor-a (TNF-a) (Moss et al., 2001) .
ADAM23 exhibits the typical structure of the ADAM family members; however, the metalloprotease domain is inactive, suggesting that it is exclusively involved in the cell adhesion process (Sagane et al., 1998) . In this context, ADAM23 was recently shown to interact specifically with avb3 integrin in an RGD-independent manner (Cal et al., 2000) . In this study, we have evaluated the mRNA expression level and methylation status of the 5 0 upstream region of the ADAM23 gene in different breast tumor cell lines and primary tumors as a further contribution to the investigation of the role of ADAM family members in human cancer.
Materials and methods

Patients and tumor cell lines
A total of 13 breast tumor cell lines (Du4475, MDA-MB-415, MDA-MB-361, MDA-MB-468, 734b, SKBR-3, MDA-MB-175, ZR-75-1, CAMA-1, MCF-7, CAL-51, PMC42 and MDA-MB-436), most of which of metastatic origin, were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained under recommended culture conditions.
In all, 15 primary ductal breast tumors were collected from patients during surgery at the Hospital do Caˆncer AC Camargo after explicit informed consent and rapidly frozen in liquid nitrogen. Paired normal and tumor tissues were obtained from all patients. Normal breast samples were commercially obtained from Clontech (Palo Alto, CA, USA).
In silico CpG island identification
We used the ADAM23 complete cDNA sequence (GenBank Accession No. AB009672) to search the publicly available human genome draft using the BLASTN program and to define the genomic structure of the ADAM23 gene. A genomic clone on chromosome 2q33-34 (GenBank Accession No. AC009225), that contained the 5 0 cDNA sequence as well as 5 0 upstream sequence was selected. An interval of 2 kb upstream and downstream from the transcription initiation site was used for in silico CpG island identification. The CpG plot program (http://www.ebi.ac.uk/emboss/cpgplot) was used for CpG island identification with the following parameters: 100 bp length, 50% G þ C and 0.6 observed/expected ratio. Putative SP1 binding sites were identified using TESS (Transcription Element Search System) program.
Analysis of DNA methylation by sequencing of sodium bissulfite-treated DNA Genomic DNA was obtained by digestion with proteinase K (Gibco BRL) followed by phenol/chloroform extraction, and was subjected to sodium bissulfite treatment to modify unmethylated cytosine to uracil using the 'CpG Modification Kit' (Intergen). Bissulfite-treated DNA was amplified by a nested-PCR protocol using the following primers: ADAMB1-F, 5 0 -TTT GTT TTG GAT AAA TTA AGG TTA-3 0 and ADAMB1-R, 5 0 -CTA CAA AAA TCA AAA CTA AAT CTC-3 0 for the first reaction; and ADAMB2-F, 5 0 -GTA TGT AAA TAT AAA GGA TTG TAG-3 0 and ADAMB2-R, 5 0 -ATA AAA ATA TAT CCT CCT AAA TAT-3 0 for the second reaction. PCR was performed in a volume of 25 ml containing 1 Â PCR Buffer (Applied Biosystems); 1.5 mM of MgCl 2 (Applied Biosystems); 200 mM of dNTPs (Amersham); 0.32 mM of each primer and 1 U of Taq GOLD (Applied Biosystems). The PCR conditions were: 941C for 12 min, 941C for 3 min, 501C for 3 min, 721C for 2 min; 941C for 3 min, 531C for 3 min, 721C for 2 min five cycles and 941C for 1 min, 551C for 1 min, 721C for 1 min 35 cycles for the first reaction and different annealing temperatures (45, 48 and 501C) for the nested reaction. Amplified products were purified using the PCR Purification Kit (Qiagen) and were sequenced directly or ligated to a TA cloning vector (Invitrogen). Six positive clones were sequenced for each cell line and 10 clones were sequenced for each primary tumor, and its normal counterpart using the vector's universal primers. The methylation percentage for each sample was calculated as the number of methylated CpG dinucleotides from the total number of CpGs analysed in all positive clones. DNA sequencing reactions were performed using the 'Dynamic TM ET terminator cycle sequencing' kit (Amersham) and an ABI3100 sequencer (Applied Biosystems) according to the manufacturer's instructions.
MCF-7 and SKBR-3 cell lines were treated with 5-Aza-CdR (Sigma). Cells ( 10 6 ) were seeded in 100 mm dishes, cultured for 48 h and treated with 1 mM of 5-Aza-CdR or left untreated. After 2-6 days, cells were washed with PBS and total RNA and DNA were isolated.
RNA isolation and RT-PCR
Total RNA was isolated using guanidine-isothiocyanate or Trizol s (Gibco BRL). The quality of RNA samples was determined by electrophoresis through agarose gels and staining with ethidium bromide. Relative intensities of the 18S and 28S RNA bands were evaluated under UV light. Reverse transcription reactions were performed with 2 mg DNA-free RNA using SUPERSCRIPT II Reverse Transcriptase (Gibco BRL). PCR was performed using ADAM23-specific primers 5 0 -TAT GAG CAG CTG TCC ACT CG-3 0 (sense) and 5 0 -CCC CAG CCT GTG CCC CCA AG -3 0 (antisense). The PCR conditions were as follows: one cycle at 941C for 4 min and 35 cycles at 941C for 45 s, 621C for 45 s and 721C for 1 min. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was amplified as an internal control. Primers for GAPDH were 5 0 -CTG CAC CAC CAA CTG CTT A-3 0 (sense) and 5 0 -CAT GAC GGC AGG TCA GGT ADAM23 methylation in breast tumors FF Costa et al C-3 0 (antisense). PCR products were resolved on 1% agarose gels, blotted onto nylon membranes and hybridized to a specific probe as described below.
Semiquantitative RT-PCR
Semiquantitative RT-PCR was carried out as described above, and reactions were terminated at different cycles: 22, 25 and 28 cycles for GAPDH and 28, 30 and 35 cycles for ADAM23 gene. PCR products were resolved on 1% agarose gels and blotted onto nylon membranes. Hybridizations were undertaken as described previously (Church and Gilbert, 1984) using a 32 P-labeled ADAM23 cDNA (Accession No. AB009672 nucleotide 1870-2800) and control probe from GAPDH cDNA (Accession No. BC023632 nucleotide 486-778).
Antibodies and Western blot
The peptide (C N N T S C L F Q P R G Y E C R D A V N E C D I T) corresponding to residues 546-570 from human ADAM 23 (Accession No. AB009672) was chemically synthesized by Bethyl Inc. (Montgomery, TX, USA) and conjugated to keyhole limpet hemocyanin (KLH) as carrier protein. Polyclonal antibodies against KLH peptide were raised in rabbits (Custom Antibody Generation Service, Bethyl) and purified IgG obtained from hyperimmune serum after Protein ASepharose chromatography according to the manufacturer's instruction (Amersham). Total cell lysates were isolated as described previously (Towbin et al., 1979) , and 80 mg of protein per sample were separated on 8% SDS-PAGE, transferred to PVDF membranes (Amersham) and immunoblotted with the antipeptide polyclonal at 1 : 2000 dilution using enhanced chemiluminescence detection system (Amersham). The antipeptide polyclonal specifically detected a single sharp band of approximately 120 kDa in breast tumor cell lines expressing the ADAM23 mRNA, but not in control cells where ADAM23 mRNA expression was not detected by RT-PCR. Membranes were stripped and reblotted with antiactin monoclonal antibody (SIGMA at 1 : 400 dilution) as a control of protein integrity.
Results
Downregulation of ADAM23 mRNA expression in breast tumor cell lines
We evaluated the ADAM23 mRNA expression by RT-PCR followed by hybridization in a panel of 12 breast tumor cell lines (Du4475, MDA-MB-415, MDA-MB-361, MDA-MB-468, 734b, MDA-MB-175, ZR-75-1, CAMA-1, MCF-7, SKBR-3, CAL-51 and PMC42) and in normal breast tissue. ADAM23 expression was detected at high levels in normal tissue, but could not be detected or was detected at a lower level in eight (66.7%) of the breast tumor cell lines (Du4475, MDA-MB-415, MDA-MB-468, 734b, MDA-MB-175, MCF-7, SKBR-3 and CAL-51) (Figure 1a ).
Aberrant methylation of the 5
0 upstream region of the ADAM23 gene Downregulation of tumor-related genes is often associated with aberrant methylation of CpG dinucleotides located at the 5 0 upstream region of the gene (Jones and Laird, 1999; Garinis et al., 2002; Jones and Baylin, 2002) . We used the human genome sequence to obtain the 5 0 upstream region of the ADAM23 gene and to identify in silico putative CpG islands. A genomic clone on chromosome 2q33-34 was obtained and two CpG islands were identified within a 2.0 kb region that includes approximately 1.0 kb upstream from the transcription initiation site, together with the first exon and intron (Figure 2 ). More than 100 CpG dinucleotides were present in this region, suggesting that methylation might influence the transcription of the ADAM23 gene.
Bissulfite genomic sequencing of a region comprising 22 CpG dinucleotides located approximately À1025 to À549 bp from the transcription start site revealed a high frequency (66.7%) of ADAM23 5 0 hypermethylation in tumor cell lines analysed. We could also observe that the methylation status was strongly correlated with ADAM23 mRNA expression (Figure 1b) . Methylation of more than 50% of the CpG dinucleotides in this region was detected by direct sequencing in nine breast tumor cell lines (Du4475, MDA-MB-415, MDA-MB-361, MDA-MB-468, 734b, MDA-MB-175, MCF-7, SKBR-3 and CAL-51) (Figure 1b) . With the exception of the MDA-MB-361 all other cell lines exhibiting hypermethylation showed altered ADAM23 expression.
Methylation density, mRNA and protein expression level
We observed that a threshold of modified CpG dinucleotides was required for the complete silencing of ADAM23 mRNA expression. To explore this observation, we analysed the methylation pattern of six independent alleles from breast tumor cell lines (PMC42; ZR-75-1, CAMA-1, 734b, MDA-MB-415) with different percentages of modified CpG dinucleotides (as determinted by direct PCR sequencing) and performed a semiquantitative RT-PCR experiment. Samples of the RT-PCR were taken at different cycles of the reaction and were analysed by Southern blotting.
As it can be seen in Figure 3a , amplification products corresponding to the ADAM23 transcript from cell lines with a lower methylation density (PMC42, CAMA-1, ZR-75-1) were detected at earlier cycles and had a higher hybridization intensity at the end of the reaction, confirming that they are expressed at higher levels than in cell lines with high methylation densities (734b, MDA-MB-415). These results indicate that at least 40-60% of the CpG dinucleotides had to be modified for a complete gene silencing and that methylation density, and not merely the presence of hypermethylation, may be of critical importance to transcription (Figure 3b ). It is interesting to note that, in this model, methylation seems to initiate mostly at CpG dinucleotides 13-19 and spread towards the promoter region, which contains two putative SP1 binding sites at CpG dinucleotides 3 and 10 ( Figure 3b) .
Western blot analysis, using specific anti-ADAM23 antibody, demonstrated protein expression in cell lines that express the ADAM23 mRNA (PMC42 and MDA-MB-436), but not in the MCF-7 cell line in which ADAM23 mRNA expression was silenced by aberrant promoter methylation (Figure 4) . These results provide a validation for the RT-PCR and methylation studies and indicate that DNA promoter hypermethylation contribute to the downregulation of ADAM23 gene at the protein level.
ADAM23 mRNA re-expression with 5 0 -Aza-dCR
To confirm the relationship between ADAM23 hypermethylation and expression, we treated MCF-7 and SKBR-3 breast tumor cell lines with the demethylating Figure 5) . A marked decrease in the original methylation status was observed at the 5 0 upstream region following treatment for both cell lines. It is worth noting that CpG islands 3 and 10 that correspond to putative SP1 binding sites became completely unmethylated after treatment (data not shown).
ADAM23 aberrant methylation in primary breast tumors
We next examined whether this epigenetic alteration could be extrapolated to primary tumors. The methylation status of the 5 0 upstream region was determined for 10 alleles of primary breast tumors as well as for their corresponding adjacent normal tissues. Tumor samples were defined as presenting aberrant methylation if their percentage of methylation was at least three times higher than that of normal samples. As observed for the breast tumor cell lines, a high frequency of promoter hypermethylation was observed. Aberrant methylation was found in nine out of 13 (69.2%) cases of primary breast tumors (Figure 6a ). It is interesting to note that primary breast tumors with a more advanced grade have a higher degree of methylation (Figure 6b ). Although these results require further verification, they suggest that ADAM23 may be downregulated during the progression of breast cancer. The ADAM23 mRNA expression was also determined in tumor and adjacent normal tissue whenever fresh preserved tissues were available for mRNA extraction. The downregulation of the ADAM23 gene was observed in tumors with a high percentage of methylation (Figure 6a ).
We observed a highly heterogeneous pattern of promoter region methylation. Although many CpG sites were affected by methylation, the exact location of methylated sites varied not only between samples but also between alleles from the same sample (Figure 6a ). This kind of heterogeneity was recently observed for the E-cadherin gene and was suggested to contribute to the dynamic phenotypic heterogeneity that drives metastatic progression in primary breast tumors (Graff et al., 2000) . The presence of unmethylated molecules in most tumor samples was also observed, and could be derived from contaminating normal tissue or infiltrating lymphocytes.
Discussion
A group of recently described proteins, the ADAMs, have stimulated interest due to their potential ability to perform two different functions related to tumorigenesis: cell adhesion and proteolysis (Wolfsberg et al., 1995a, b; Black and White, 1998; Primakoff and Myles, 2000) . As a further step to determine the role of ADAM family members in human cancers, we examined the expression level and methylation status of the 5 0 upstream region of the ADAM23 gene in different breast tumor cell lines as well as in primary breast tumors.
ADAM23 expression was detected in normal tissue, but could not be detected or was detected at a lower level in eight (66.7%) of the breast tumor cell lines examined. The presence of methylation in a region located approximately 0.5 kb from the transcription initiation site of the ADAM23 gene was strongly associated with the altered mRNA and protein expression pattern. This association was further confirmed in experiments using the demethylating agent 5 0 -Aza-dCR. We also found ADAM23 tumor-specific hypermethylation in 69.2% primary breast tumors.
A threshold of 40-60% of modified CpG dinucleotides was required for the complete silencing of ADAM23 mRNA expression. Similarly, Cameron et al. (1999) have shown that a threshold of 40% was required for silencing the human p15 gene in acute leukemia.
The existence of such a threshold has also been demonstrated in experiments using plasmid constructs containing a different number of methylated dinucleotides cloned at different positions relative to a specific promoter (Ohtani-Fujita et al., 1993; Hsieh, 1994; Curradi et al., 2002) . The presence of intra-allelic variation and the requirement of a threshold for complete gene silencing supports the view that aberrant methylation is a consequence of a decrease in normal transcription activity and involves progressive methylation towards the regulatory transcription sites (Clark and Melki, 2002; Turker, 2002) . Alterations of the methylation pattern have now been widely observed in tumors. Global hypomethylation, increased DNA methyltransferase activity and local DNA hypermethylation of CpG islands located in the 5 0 regulatory regions of tumor-related genes have all been reported (Ehrlich, 2002; Esteller, 2002; Robertson, 2002) . Here we provide, for the first time, evidence for the epigenetic silencing of a member of the ADAM family, suggesting a potential role of this new family of adhesion molecules in cancer.
A growing body of evidence suggests that alterations in the adhesion properties of neoplasic cells have a pivotal role in the progression of cancer and metastasis formation (Cavallaro and Christofori, 2001; Okegawa et al., 2002) . Loss of intercellular adhesion and desquamation of cells from the lamina propria allows malignant cells to escape from their site of origin, degrade the extracellular matrix, invade and metastize. Since ADAM23 was recently shown to act as an (Cal et al., 2000) , gene silencing caused by aberrant promoter methylation may result in abnormal cell-cell interactions and favor cell migration during metastatic process.
In this context, we have observed that primary breast tumors with a more advanced grade have a higher degree of ADAM23 promoter hypermethylation. We also observed that, although many CpG sites were affected by methylation, the exact location of methylated sites varied not only between tumor samples but also between alleles from the same sample. The presence of this intra-allelic heterogeneity in the methylation pattern suggests that methyltransferase enzyme does not faithfully maintain methylation at individual CpG sites. This fact could reflect a type of epigenetic instability, which, in turn, may provide a growth advantage to the cell leading to the selection of those with the most dense methylation profile during metastatic progression. This kind of epigenetic instability was recently observed for the E-cadherin gene and was suggested to contribute to the dynamic, phenotypic heterogeneity that drives metastatic progression in primary breast tumors (Graff et al., 2000) . Further studies are underway to support the role of ADAM23 (and other ADAM family members) in tumor progression and to explore its potential use as a tumor marker.
Abbreviations ADAM, A Desintegrin And Metalloprotease domain; MDC, Metalloprotease/Disintegrin/Cysteine rich; TACE, TNF-a converting enzyme; TNF-a, tumor necrosis factor-a; CAM, cell adhesion molecule ; 5 0 -Aza-dCR, 5 0 -Aza-2 0 -deoxycytidine.
